Business Description
Valerio Therapeutics
ISIN : FR0010095596
Compare
Compare
Traded in other countries / regions
ALVIO.FranceC4X.Germany0NWK.UKONXEO.Denmark IPO Date
2014-08-01Description
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.3 | |||||
| Equity-to-Asset | 0.14 | |||||
| Debt-to-Equity | 3.29 | |||||
| Debt-to-EBITDA | -0.82 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -2.22 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -18.5 | |||||
| 3-Year EPS without NRI Growth Rate | -20.4 | |||||
| 3-Year FCF Growth Rate | -27.3 | |||||
| 3-Year Book Growth Rate | -36.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 46.2 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | |||||
| Quick Ratio | 0.9 | |||||
| Cash Ratio | 0.41 | |||||
| Days Sales Outstanding | 324.81 | |||||
| Days Payable | 2670.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.2 | |||||
| Shareholder Yield % | -11.59 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.75 | |||||
| Operating Margin % | -951.03 | |||||
| Net Margin % | -1040.66 | |||||
| FCF Margin % | -870.55 | |||||
| ROE % | -140.41 | |||||
| ROA % | -54.29 | |||||
| ROIC % | -62.77 | |||||
| ROC (Joel Greenblatt) % | -1306.41 | |||||
| ROCE % | -77.19 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.08 | |||||
| PB Ratio | 3.04 | |||||
| EV-to-EBIT | -1.1 | |||||
| EV-to-EBITDA | -1.32 | |||||
| EV-to-Revenue | 11.32 | |||||
| EV-to-FCF | -1.3 | |||||
| Price-to-Median-PS-Value | 0.53 | |||||
| Earnings Yield (Greenblatt) % | -90.91 | |||||
| FCF Yield % | -135.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Valerio Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 14.08 | ||
| EPS (TTM) (kr) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (kr) | 0 | ||
| 20-Day SMA (kr) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (kr) | 1.3 - 1.3 | ||
| Shares Outstanding (Mil) | 154.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Valerio Therapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Valerio Therapeutics Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Valerio Therapeutics Frequently Asked Questions
What is Valerio Therapeutics(OCSE:ONXEO)'s stock price today?
The current price of OCSE:ONXEO is kr1.30. The 52 week high of OCSE:ONXEO is kr1.30 and 52 week low is kr1.30.
When is next earnings date of Valerio Therapeutics(OCSE:ONXEO)?
The next earnings date of Valerio Therapeutics(OCSE:ONXEO) is 2025-04-19 Est..
Does Valerio Therapeutics(OCSE:ONXEO) pay dividends? If so, how much?
Valerio Therapeutics(OCSE:ONXEO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers